HAIFA, Israel, 23 July 2020 – Researchers at the Israeli Rabin Medical Cinput Hospital (composed of Beilinson and Hasharon hospitals) in collaboration with MeMed have published forward-looking knowledge of the potential usefulness of IP-10 studies, an immune host biomarker, in the control of care and therapy of patients with severe COVID-1nine infection.
Initial knowledge of the prospective study shows that rapid and uninterrupted measurements of IP-10, an applicable biomarker with inflammatory disease, which adds infectious ailments and immune dysfunction, is also a valuable resource for predicting disease severity and progression, tracking inflammatory prestige, and customizing forms of therapy for patients with severe COVID-19. The results of the studies were published in medRxiv (the prepress server for the sciences of fitness).
Dr. Shaul Lev, head of the General Intensive Care Department at Hasharon Hospital at Rabin Medical Cinput and lead authors of the study, added: “This is the first study that inspects how real-time measurements of IP-10, a host- The immune protein biomarker is also used to control and regroup beyond inflammation due in severe patients with COVID-1 Nine. It presents initial evidence suggesting that additional studies are warranted and that a rapid and uninterrupted measurement of the host’s immune reaction with MeMed Key ™ can mold COVID-1 nine therapy decisions and take into account changes in clinical practice that personalize the care of individual patients.
The Rabin Medical Cinput study team used MeMed’s pioneering generation platform, MeMed Key ™, which allows highly sensitive measurements of various host immune proteins, adding IP-10, in minutes when needed. During the study, researchers evaluated more than 502 serial measurements of IP-10 of 52 patients admitted to the ward and intensive care unit at Hasharon Hospital in Rabin Medical Cinput. The high degrees of IP-10 were similar with a severity and mortality of COVID-191 design. Personalized immunomodulation, healing interventions aimed at modifying the immune response, has been shown to decrease IP-10 grades.
They were Eden, co-founder and CEO of MeMed, added: “We are very happy to be a wife with our colleagues at Rabin Medical Cinput for this core study. The collaboration builds on years of paintings to expand the generation that decodes the signals of the immune formula and provide doctors with direct critical information to make more dissatisfied therapeutic decisions. We are grateful to our study partners and proud to connect a team that solves critical clinical dilemmas, with responses that concrete care and outcomes for PATIENTS with COVID-19.”
About MeMed Our task is to transcend the complex signals of the immune formula into undeniable data that transbides the way diseases are diagnosed and treated, which deeply benefits patients and society. For additional information about MeMed, visit https://www.me-med.com. About MeMed Key ™ MeMed Key ™ is a fully friendly exclusive generation platform, allowing highly sensitive measurements of multiple proteins in minutes to the point of need. It paves the way for quantifying a wide diversity of huguy proteins in healthy and pathological conditions, where and when it is important. The MeMed Key ™ progression program was the best friend funded by the U.S. Department of Defense and the European Commission. MeMed Key ™ has obtained the CE marking in Europe and the AMAR authorization of the Israeli Health Minischeck.
MeMed Contacts: Media: Adee Mor, Vice President of Marketing, [email protected] IR: Kfir Emmer, Vice President of Finance, [email protected] Phone: 972-4-8500302